New drug approval–better in the U.S. or Europe?

According to an article in the journal Health Affairs, new cancer drugs are approved more quickly in the U.S. than in Europe.  The study, published recently as an oline exclusive, compared the initial approval of 35 oncology drugs by the FDA and the European Medicines Agency.  The median time for approval in the U.S. was about 6 … Continue reading New drug approval–better in the U.S. or Europe?